**Author Information** An event is serious (based on the ICH definition) when the patient outcome is:\* death\* life-threatening\* hospitalisation\* disability\* congenital anomaly\* other medically important event

In a single-centre, cross-sectional study of 75 patients, who had coronavirus disease-2019 (COVID-19), were treated at the University of Health Sciences Samsun Training and Research Hospital, Turkey between 20 March 2020 and 10 April 2020, of whom, two patients \[*sexes and ages not stated*\] were described, who developed ventricular tachycardia during off-label treatment with azithromycin and hydroxychloroquine for Covid-19. Additionally, both patients also received off-label treatment with favipiravir for COVID-19 \[*dosages*, *routes, durations of treatments with reactions onsets and outcomes not stated*\].

Both patients were diagnosed with COVID-19 and were admitted to an ICU. Subsequently, both patients started receiving off-label treatment with azithromycin, favipiravir and hydroxychloroquine. During ICU admission, both patients developed ventricular tachycardia. Prior to initiation of treatment, both patients had elevated Tp-e intervals and Tp-e/QTc ratios, while QTc intervals were normal. However, after treatment, further increase in Tp-e intervals, Tp-e/QTc ratios and QTc intervals were observed.
